APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/10/2026
Back to search
Official data from USPTO
DEVATIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
08/10/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
11/20/2019
Registration date
11/17/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/17/2020
Last transaction
08/10/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
TR
Examiner
FALK, JONATHAN ROBERT
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "DEVATIS" with the "D" in light blue and remaining letters in dark blue all within a black square. The color white represents background or transparent areas only and is not claimed as a feature of the mark.
Holders and representatives
Holders
DEVA HOLDING ANONIM SIRKETI
Representatives
Nicholas D. Wells Legends Law Group, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in treating by inhibiting the growth of tumorsas antiparasiticsfor treatment of the nervous systemsorthopedic and musculoskeletal diseaserespiratory diseasegenital and urologic diseaseendocrinology diseasecardiovascular diseasedermatological diseasemetabolic diseasegastrointestinal diseasehormonal diseasesophthalmological diseasecancer and diseases of the bloodfor use in treating immune functionpsychiatric disordersfatiguesexual disfunction; veterinary preparations for use in treating by inhibiting the growth of tumorsas antiparasiticsfor treatment of the nervous systemsorthopedic and musculoskeletal diseaserespiratory diseasegenital and urologic diseaseendocrinology diseasecardiovascular diseasedermatological diseasemetabolic diseasegastrointestinal diseasehormonal diseasesophthalmological diseasecancer and diseases of the bloodfor use in treating immune functionpsychiatric disordersfatiguesexual disfunction; sanitary preparations for medical purposes; dietetic foods namelyfood supplements and dietary supplements adapted for medical use; dietetic sugar for medical use; food for babies; dietary supplements for humans and animals; medical plastersmaterials for dressings; material for stopping teethdental wax; all purpose disinfectants; preparations for destroying vermin; fungicidesherbicides
Publications
History of USPTO decisions and trademark events.
33 publications found
ES71
TEAS SECTION 71 RECEIVED
05/11/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/26/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/17/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/06/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/18/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/04/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/20/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
02/20/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/17/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
11/17/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/01/2020
PUBO
PUBLISHED FOR OPPOSITION
09/01/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/27/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/25/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/25/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/25/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/11/2020
GNRT
NON-FINAL ACTION E-MAILED
05/11/2020
CNRT
NON-FINAL ACTION WRITTEN
05/11/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/18/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/18/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/18/2020
RFNT
REFUSAL PROCESSED BY IB
04/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/24/2020
RFRR
REFUSAL PROCESSED BY MPU
03/24/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/04/2020
CNRT
NON-FINAL ACTION WRITTEN
03/03/2020
MAFR
APPLICATION FILING RECEIPT MAILED
02/29/2020
DOCK
ASSIGNED TO EXAMINER
02/25/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/25/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/20/2020
Continuous trademark protection
Get notified about every new filing that threatens DEVATIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.